Subscribe To
RXST / RxSight, Inc. (RXST) Q3 2022 Earnings Call Transcript
RXST News
By Seeking Alpha
October 27, 2023
RxSight: Losing Altitude Despite 'Best Of Breed' Platform
Today we look at RxSight, Inc., a small ocular focused medical device company focused on transforming the cataract surgery market. The company is deli more_horizontal
By Zacks Investment Research
September 7, 2023
RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors
After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at more_horizontal
By Zacks Investment Research
August 7, 2023
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss o more_horizontal
By Zacks Investment Research
June 30, 2023
Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?
RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not hel more_horizontal
By Seeking Alpha
May 13, 2023
RxSight, Inc. (RXST) Q1 2023 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - Preside more_horizontal
By Zacks Investment Research
May 9, 2023
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss o more_horizontal
By Zacks Investment Research
April 11, 2023
Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal
By Zacks Investment Research
March 13, 2023
How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%
The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is more_horizontal